Trial intelligence / Profile preview

Paclitaxel + bevacizumab versus paclitaxel + capecitabine + bevacizumab for first-line HER2-negative recurrent/metastatic breast cancer

NL-OMON20125Phase 2Recruiting

Sponsor

VU University medical center Prof. E. Boven, MD, PhD, medical oncologist De Boelelaan 1117 1081 HV Amsterdam Phone: 020-444 4336 E-mail: [email protected] together with: Borstkanker Onderzoek Groep(BOOG) Dr. A.E. van Leeuwen-Stok, research-manager P.O. Box 9236, 1006 AE Amsterdam Phone: 020-346 2547 Fax: 020-346 2525 E-mail: [email protected]

Start

May 2007

Modality

Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules

Countries

1